Hua Gong
Vice President - Translational Medicine BBOT (BridgeBio Oncology Therapeutics)
Dr. Hua Gong is Vice President of Translational Medicine at BBOT, bringing more than two decades of experience in drug and diagnostic discovery and development, with a focus on oncology, immuno-oncology, and autoimmune diseases.
Before joining BBOT, Hua served as Senior Vice President of Translational Medicine at Zai Lab, where she built biomarker strategies across early- and late-stage programs, contributed to the approval of two drugs, advanced multiple others, and played a pivotal role in expanding the company’s global pipeline.
She previously held the role of Chief Operating Officer and Head of Precision Medicine at Adagene, where she was instrumental in the company’s successful IPO in 2021. Earlier in her career, Hua held leadership roles at Navigate/Novartis, where her precision medicine expertise supported the development and approval of seven oncology drugs. Prior to that, she took on positions of increasing responsibility at Premier Research, Prometheus, and Pfizer.
Seminars
- Defining and achieving the optimal analytical thresholds for sensitivity and specificity in line with intended clinical use – how sensitive is too sensitive?
- Discussing strategies to minimize CHIP related false positives and false negatives without compromising turnaround time or trial feasibility
- Refining analytical validation data strategies to support regulatory submissions, companion diagnostic partnerships, and confident clinical decision-making
